<DOC>
	<DOC>NCT02752516</DOC>
	<brief_summary>A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics.To further study the pharmacokinetic characteristics of Anlotinib in the human body, recommend a reasonable regimen for subsequent research.</brief_summary>
	<brief_title>A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics</brief_title>
	<detailed_description />
	<criteria>Histological documentation of Advanced solid tumors except the digestive tract tumors,at least one measurable lesion (by RECIST1.1) Lack of the standard treatment or treatment failure 1865 years,ECOG PS:01,Life expectancy of more than 3 months 30 Days or more from the last cytotoxic therapy Main organs function is normal Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be nonlactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped Patients should participate in the study voluntarily and sign informed consent Patients who are used by anlotinib Patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea, intestinal obstruction etc.) Brain metastases patients with symptoms or symptoms controlled &lt; 3 months Patients with any severe and/or unable to control diseases，including： 1. Blood pressure unable to be controlled ideally(systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg); 2. Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥480ms) and patients with Grade 1 or higher congestive heart failure (NYHA Classification); 3. Patients with active or unable to control serious infections; 4. Patients with cirrhosis, decompensated liver disease, or active hepatitis; 5. Patients with poorly controlled diabetes (fasting blood glucose(FBG)＞10mmol/L) 6. Urine protein ≥ ++，and 24hour urinary protein excretion＞1.0 g confirmed Patients with nonhealing wounds or fractures Patients with any CTC AE Grade 1 or higher bleeding events occurred in the lungs or any CTC AE Grade 2 or higher bleeding events occurred within 4 weeks prior to assignment;Patients with any physical signs of bleeding diathesis or receiving thrombolysis and anticoagulation Patients with drug abuse history and unable to get rid of or Patients with mental disorders Patients participated in other anticancer drug clinical trials within 4 weeks History of immunodeficiency Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>